Sorrento becomes one-stop ADC shop with $11.6m Concortis buy
This article was originally published in Scrip
Executive Summary
The recent spending spree by Sorrento Therapeutics has come to an end with the acquisition of Concortis BioSystems whose linkers and cytotoxic agents will be combined with antibodies from Sorrento's G-MAB library to create a one-stop antibody-drug conjugate (ADC) shop.